Media Articles Related to Quadramet (Samarium SM 153 Lexidronam Pentasodium)
Data presented at NANS 2014 demonstrate long-term, low back pain relief with Spectra Spinal Cord Stimulator System
Source: Medical Devices / Diagnostics News From Medical News Today [2014.12.20]
New retrospective data evaluating the Boston Scientific Corporation (NYSE: BSX) Precision Spectra™ Spinal Cord Stimulator (SCS) System demonstrate that the device provided sustained, highly...
Novel agent decreases neuropathic pain in patients with type 2 diabetes
Source: Diabetes News From Medical News Today [2014.12.19]
Molecular Medicine, a peer-reviewed biomedical journal published by the Feinstein Institute Press, published the results of a new study reporting clinically significant pain reduction in type 2...
The difficulties of treating shoulder pain in baseball pitchers
Source: Bones / Orthopedics News From Medical News Today [2014.12.15]
Results of treating shoulder pain in baseball pitchers and other throwing athletes are not as predictable as doctors, patients and coaches would like to think, according to a report in the journal...
Commonly prescribed painkiller not effective in controlling lower back pain
Source: Seniors / Aging News From Medical News Today [2014.12.15]
A new study in the journal Neurology shows that pregabalin is not effective in controlling the pain associated with lumbar spinal stenosis, the most common type of chronic lower back pain in older...
Painful Hands, Hurting Hearts?
Source: MedPage Today Rheumatology [2014.12.15]
(MedPage Today) -- Symptomatic hand osteoarthritis was linked with coronary heart disease.
Published Studies Related to Quadramet (Samarium SM 153 Lexidronam Pentasodium)
[Cost-effectiveness analysis of samario-153 (Quadramet) for the treatment of patients with prostate cancer and bone metastases] [2005.06]
CONCLUSION: Samarium-153 (Quadramet) is cost-effective in treating pain in patients with prostate cancer and bone metastases.
A comparative study of samarium-153-ethylenediaminetetramethylene phosphonic acid with pamidronate disodium in the treatment of patients with painful metastatic bone cancer. [2003.04]
CONCLUSION: The data showed that the therapeutic efficacy of (153)Sm-EDTPM was higher than that of pamidronate disodium (for pain relief maintained more than 3 weeks) and its incidence of blood toxicity was also higher than that of pamidronate disodium. Copyright 2003 S. Karger AG, Basel
Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China. [1999.01]
A multicentre trial was organized in China as part of an international coordinated research project to study the efficacy and toxicity of single-dose samarium-153 ethylene diamine tetramethylene phosphonate (EDTMP) as a palliative treatment for painful skeletal metastases... Further studies are needed to identify better ways of determining the appropriate dose in the individual case and the efficacy of treatment.
Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. [1998.04]
PURPOSE: To evaluate the effectiveness and safety of samarium-153 (153Sm) lexidronam (EDTMP) in a double-blind, placebo-controlled study... CONCLUSION: A single dose of 1.0 mCi/kg of 153Sm-EDTMP provided relief from pain associated with bone metastases. Pain relief was observed within 1 week of administration and persisted until at least week 16 in the majority of patients who responded.
Adverse events in the long-term follow-up of patients treated with samarium Sm 153 lexidronam for osseous metastases. [2011.10.01]
CONCLUSIONS: Our observation of new-onset, acute and transient edema and neuropathy after samarium Sm 153 lexidronam and of a relationship between edema and post-samarium Sm 153 lexidronam chemotherapy suggests the need for re-examination of patients in past series or for a prospective investigation with nonhematologic adverse events as a primary endpoint. Copyright (c) 2011 Elsevier Inc. All rights reserved.
Clinical Trials Related to Quadramet (Samarium SM 153 Lexidronam Pentasodium)
153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer [Recruiting]
- No treatment is known to improve survival for prostate cancer patients who have not
been helped by previous treatments with hormones and chemotherapy.
- An experimental vaccine called PSA/TRICOM contains genes for a protein produced by
prostate cancer cells called prostate-specific antigen (PSA). The vaccine can trigger
the immune system to make cells that may be able to recognize and attack the cancer
cells that make PSA.
- GM-CSF is an approved drug that is usually given to increase a patient's white blood
cell count or to stimulate the immune system.
- 153Sm-EDTMP is a radioactive drug that has been approved for many years to treat
advanced prostate cancer. It is given through a vein and can be targeted directly to
tumors in the bone where it can relieve pain caused by bone lesions. Radiation also
increases the level of certain proteins inside the tumor, making it easier for the
immune system to find and kill the tumor cells.
- When laboratory mice were given just vaccine, just radiation, or a combination of both,
the combination was most effective in treating tumors.
- To determine if combined treatment with PSA/TRICOM vaccine and 153Sm-EDTMP radiation can
delay progression of prostate cancer better than radiation alone.
- Patients who have advanced prostate cancer that has worsened despite treatments with
hormones, have two or more bone lesions related to their prostate cancer, and have had prior
treatment with docetaxel chemotherapy.
- Patients are randomly assigned to receive radiation alone (Arm A) or radiation with
vaccine and sargramostim (Arm B).
- Arm A receives 153Sm-EDTMP radiation starting on study day 8 and repeated every 12
- Arm B receives a priming vaccine on study day 1 and radiation on day 8. Radiation
therapy is repeated every 12 weeks. Boosting vaccines are given on days 15 and 29 and
then monthly. GM-CSF is given with each vaccination (on the day of the vaccination and
for the next 3 days) to enhance the immune response. Vaccinations and GM-CSF are given
as injections under the skin, usually in the thigh. Radiation therapy is given through
- Patients are monitored regularly with physical examinations, blood and urine tests, and
scans to evaluate safety and treatment response.
- Patients who are HLA-A2-positive undergo apheresis, a procedure similar to donating
blood, for obtaining immune cells called lymphocytes to measure the immune response to
Sm-EDTMP and Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases [Recruiting]
- To determine the time to progression in subjects with breast cancer metastatic to bone
only treated with 153Sm-EDTMP and Autologous Peripheral Blood Stem Cell Transplantation
- To determine the overall survival at one year.
- To determine the efficacy of 153Sm-EDTMP at 6 months.
- To assess pain in subjects treated with 153Sm-EDTMP.
- To determine the safety of 153Sm-EDTMP.
Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma [Active, not recruiting]
RATIONALE: Radioactive drugs, such as samarium Sm 153 lexidronam pentasodium, may carry
radiation directly to cancer cells and not harm normal cells. Bortezomib may stop the growth
of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood
flow to the cancer. Bortezomib may also make cancer cells more sensitive to radiation
therapy. Giving samarium Sm 153 lexidronam pentasodium together with bortezomib may kill more
PURPOSE: This phase I/II trial is studying the side effects and best dose of bortezomib when
given together with samarium Sm 153 lexidronam pentasodium and to see how well they work in
treating patients with relapsed or refractory multiple myeloma.
Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain [Active, not recruiting]
RATIONALE: Radioactive drugs, such as samarium Sm 153 lexidronam pentasodium, may carry
radiation directly to cancer cells and not harm normal cells. Zoledronic acid and pamidronate
may help relieve bone pain caused by multiple myeloma. Giving samarium Sm 153 lexidronam
pentasodium together with zoledronic acid or pamidronate may be an effective treatment for
PURPOSE: This phase I/II trial is studying the side effects and best dose of samarium Sm 153
lexidronam pentasodium when given together with zoledronic acid or pamidronate and to see how
well it works in treating patients with relapsed or refractory multiple myeloma and bone
Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer [Recruiting]
RATIONALE: Giving samarium Sm 153 lexidronam pentasodium and 3-dimensional (3-D) conformal
radiation therapy or intensity-modulated radiation therapy may keep prostate cancer from
growing in patients with rising prostate-specific antigen (PSA) levels after radical
prostatectomy for prostate cancer.
PURPOSE: This phase II trial is studying how well samarium Sm 153 lexidronam pentasodium and
3-D conformal radiation therapy or intensity-modulated radiation therapy work in treating
patients with rising PSA levels after radical prostatectomy for prostate cancer.